Jessica D McDermott1, Megan Eguchi2, William A Stokes3, Arya Amini4, Mohammad Hararah5, Ding Ding6, Allison Valentine2, Cathy J Bradley2, Sana D Karam3. 1. 1 Department of Medical Oncology, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA. 2. 2 Department of Health Systems, Management and Policy, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 3. 3 Department of Radiation Oncology, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA. 4. 4 Department of Radiation Oncology, City of Hope, Duarte, California, USA. 5. 5 Department of Otolaryngology, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA. 6. 6 University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA.
Abstract
OBJECTIVE: Opioid use and abuse is a national health care crisis, yet opioids remain the cornerstone of pain management in cancer. We sought to determine the risk of acute and chronic opioid use with head and neck squamous cell cancer (HNSCC) treatment. STUDY DESIGN: Retrospective population-based study. SETTING: Surveillance, Epidemiology and End Results (SEER)-Medicare database from 2008 to 2011. SUBJECTS AND METHODS: In total, 976 nondistant metastatic oral cavity and oropharynx patients undergoing cancer-directed treatment enrolled in Medicare were included. Opiate use was the primary end point. Univariate and multivariable logistic analyses were completed to determine risk factors. RESULTS: Of the patients, 811 (83.1%) received an opioid prescription during the treatment period, and 150 patients (15.4%) had continued opioid prescriptions at 3 months and 68 (7.0%) at 6 months. Opioid use during treatment was associated with prescriptions prior to treatment (odds ratio [OR], 3.28; 95% confidence interval [CI], 2.11-5.12) and was least likely to be associated with radiation treatment alone (OR, 0.35; 95% CI, 0.18-0.68). Risk factors for continued opioid use at both 3 and 6 months included tobacco use (OR, 2.23; 95% CI, 1.05-4.71 and OR, 3.84; 95% CI, 1.44-10.24) and opioids prescribed prior to treatment (OR, 3.84; 95% CI, 2.45-5.91 and OR, 3.56; 95% CI, 1.95-6.50). Oxycodone prescribed as the first opioid was the least likely to lead to ongoing use at 3 and 6 months (OR, 0.33; 95% CI, 0.17-0.62 and OR, 0.26; 95% CI, 0.10-0.67). CONCLUSION: Patients with oral/oropharyngeal cancer are at a very high risk for receiving opioids as part of symptom management during treatment, and a significant portion continues use at 3 and 6 months after treatment completion.
OBJECTIVE: Opioid use and abuse is a national health care crisis, yet opioids remain the cornerstone of pain management in cancer. We sought to determine the risk of acute and chronic opioid use with head and neck squamous cell cancer (HNSCC) treatment. STUDY DESIGN: Retrospective population-based study. SETTING: Surveillance, Epidemiology and End Results (SEER)-Medicare database from 2008 to 2011. SUBJECTS AND METHODS: In total, 976 nondistant metastatic oral cavity and oropharynx patients undergoing cancer-directed treatment enrolled in Medicare were included. Opiate use was the primary end point. Univariate and multivariable logistic analyses were completed to determine risk factors. RESULTS: Of the patients, 811 (83.1%) received an opioid prescription during the treatment period, and 150 patients (15.4%) had continued opioid prescriptions at 3 months and 68 (7.0%) at 6 months. Opioid use during treatment was associated with prescriptions prior to treatment (odds ratio [OR], 3.28; 95% confidence interval [CI], 2.11-5.12) and was least likely to be associated with radiation treatment alone (OR, 0.35; 95% CI, 0.18-0.68). Risk factors for continued opioid use at both 3 and 6 months included tobacco use (OR, 2.23; 95% CI, 1.05-4.71 and OR, 3.84; 95% CI, 1.44-10.24) and opioids prescribed prior to treatment (OR, 3.84; 95% CI, 2.45-5.91 and OR, 3.56; 95% CI, 1.95-6.50). Oxycodone prescribed as the first opioid was the least likely to lead to ongoing use at 3 and 6 months (OR, 0.33; 95% CI, 0.17-0.62 and OR, 0.26; 95% CI, 0.10-0.67). CONCLUSION:Patients with oral/oropharyngeal cancer are at a very high risk for receiving opioids as part of symptom management during treatment, and a significant portion continues use at 3 and 6 months after treatment completion.
Entities:
Keywords:
Medicare; SEER; head and neck squamous cell cancer; opiate; opioid; oral cavity cancer; oropharyngeal cancer; pain
Authors: Marisa R Buchakjian; Andrew B Davis; Sebastian J Sciegienka; Nitin A Pagedar; Steven M Sperry Journal: Ann Otol Rhinol Laryngol Date: 2017-08-03 Impact factor: 1.547
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet Journal: J Gen Intern Med Date: 2016-08-02 Impact factor: 5.128
Authors: J Nguyen; K Luk; D Vang; W Soto; L Vincent; S Robiner; R Saavedra; Y Li; P Gupta; K Gupta Journal: Br J Anaesth Date: 2014-05-26 Impact factor: 9.166
Authors: Thomas Ciesielski; Reethi Iyengar; Amit Bothra; Dave Tomala; Geoffrey Cislo; Brian F Gage Journal: Am J Med Date: 2016-03-09 Impact factor: 4.965
Authors: Susan Furness; Anne-Marie Glenny; Helen V Worthington; Sue Pavitt; Richard Oliver; Jan E Clarkson; Michaelina Macluskey; Kelvin Kw Chan; David I Conway Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Jennifer P March; James Y Lim; Katherine L Manzione; Michelle Buncke; Maisie L Shindo Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-06-01 Impact factor: 8.961
Authors: Leif-Erik D Schumacher; Zoukaa B Sargi; Melissa Masforroll; Deukwoo Kwon; Wei Zhao; Maria A Rueda-Lara; Laura M Freedman; Nagy Elsayyad; Stuart E Samuels; Matthew C Abramowitz; Michael A Samuels Journal: Head Neck Date: 2019-11-30 Impact factor: 3.147
Authors: Lucas K Vitzthum; Paul Riviere; Paige Sheridan; Vinit Nalawade; Rishi Deka; Timothy Furnish; Loren K Mell; Brent Rose; Mark Wallace; James D Murphy Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Lu Chen; Jessica Chubak; Onchee Yu; Gaia Pocobelli; Rebecca A Ziebell; Erin J Aiello Bowles; Monica M Fujii; Andrew T Sterrett; Jennifer M Boggs; Andrea N Burnett-Hartman; Debra P Ritzwoller; Rebecca A Hubbard; Denise M Boudreau Journal: Cancer Causes Control Date: 2019-10-30 Impact factor: 2.506
Authors: Sondos Zayed; Cindy Lin; R Gabriel Boldt; Jinka Sathya; Varagur Venkatesan; Nancy Read; Lucas C Mendez; Dwight E Moulin; David A Palma Journal: Adv Radiat Oncol Date: 2020-10-26
Authors: Mary Falcone; Chongliang Luo; Justin E Bekelman; Caryn Lerman; Yong Chen; David Birtwell; Martin Cheatle; Rui Duan; Peter E Gabriel; Lifang He; Emily M Ko; Heinz-Josef Lenz; Nebojsa Mirkovic; Danielle L Mowery; E Andrew Ochroch; E Carter Paulson; Emily Schriver; Robert A Schnoll Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-28 Impact factor: 4.254